High-resolution flow cytometry: A suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment

International Journal of Medical Sciences

Volumn 6, Issue 6, 2009, Pages 338-347

  Braun, Klaus ^a   Ehemann, Volker ^b   Wiessler, Manfred ^a   Pipkorn, Ruediger ^a   Didinger, Bernd ^b   Mueller, Gabriele ^a   Waldeck, Waldemar ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Flow cytometry; Prostate cancer cells; TMZ BioShuttle

Indexed keywords

DNA; PEPTIDE; TEMOZOLOMIDE;

ANEUPLOIDY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL INCLUSION; CELL NUCLEUS; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIGATION; NUCLEAR LOCALIZATION SIGNAL; PROSTATE CANCER; SENSITIVITY ANALYSIS;

EID: 74549215029     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.6.338     Document Type: Article

References (62)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ. Cancer statistics. 2007. CA Cancer J Clin. 2007; 57: 43-66
2. Li Y, and Cozzi PJ. Targeting uPA/uPAR in prostate cancer. Cancer Treat. Rev. 2007;33(6):521-7
3. Catalona WJ and Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-1842
4. Walsh PC. The status of radical prostatectomy in the United States in 1993: where do we go from here? J. Urol. 1994; 152: 1816
5. Hanks GE, Hanlon AL, Epstein B, and Horwitz EM. Dose response in prostate cancer with 8-12 years' follow-up. International Journal of Radiation Oncology Biology Physics 2002; 54: 427-435
6. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, and Fuks Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1998; 41: 491-500
7. Bratt O. The urologist's guide to low dose-rate interstitial brachytherapy with permanent seed implants for localized prostate cancer. BJU. Int. 2007; 99: 497-501
8. Sharifi N, Gulley JL, and Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244
9. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A, and Tannock IF. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1998; 16: 2272-2279
10. Autorino R, Di LG, Damiano R, De PS, and D'Armiento M. Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives. Urol Int. 2003; 70: 1-14
11. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de WR, and Eisenberger M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 2007; 25: 3965-3970
12. Garrett-Mayer E, Parmigiani G, Zhong X, Cope L, and Gabrielson E. Cross-study validation and combined analysis of gene expression microarray data. Biostatistics. 2008 Apr;9(2):333-54
13. Hainsworth JD, Meluch AA, Spigel DR, Barton J, Simons L, Meng C, Gould B, and Greco FA. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin. Genitourin. Cancer 2007; 5: 278-283
14. Di LG, Autorino R, Giuliano M, Morelli E, Giordano A, Napodano G, Russo A, Benincasa G, D'Armiento M, Altieri V, and De PS. Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology 2007; 69: 347-351
15. Ueda T, Suzuki H, Akakura K, Ishihara M, Kamiya N, Komiya A, Shimbo M, Suyama T, Sakamoto S, and Ichikawa T. Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer. Hinyokika Kiyo 2006; 52: 515-521
16. Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP, Beuzeboc P, Demkow T, and Oudard S. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann. Oncol. 2004; 15: 1613-1621
17. Reilly DS, Tomassini N, Bevins CL, and Zasloff M. A Paneth cell analogue in Xenopus small intestine expresses antimicrobial peptide genes: conservation of an intestinal host-defense system. J. Histochem. Cytochem. 1994; 42: 697-704
18. Small EJ, Srinivas S, Egan B, McMillan A, and Rearden TP. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J. Clin. Oncol. 1996; 14: 1617-1625
19. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, and Mason MD. Chemotherapy for hormone-refractory prostate cancer. Cochrane. Database Syst. Rev. 2006 Oct 18; (4):CD005247
20. Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, and Eisenhauer E. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann. Oncol. 2006; 17: 952-956
21. van Brussel JP, Busstra MB, Lang MS, Catsburg T, Schroder FH, and Mickisch GH. A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother. Pharmacol. 2000; 45: 509-512
22. Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, and Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist. Updat. 2007; 10: 51-58
23. Dahiya R, Yoon WH, Boyle B, Schoenberg S, Yen TS, and Narayan P. Biochemical, cytogenetic, and morphological characteristics of human primary and metastatic prostate cancer cell lines. Biochem. Int. 1992; 27: 567-577
24. Stone KR, Mickey DD, Wunderli H, Mickey GH, and Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 1978; 21: 274-281
25. Ehemann V, Hashemi B, Lange A, and Otto HF. Flow cytometric DNA analysis and chromosomal aberrations in malignant glioblastomas. Cancer Lett 1999; 138: 101-106
26. Braun K, Peschke P, Pipkorn R, Lampel S, Wachsmuth M, Waldeck W, Friedrich E, and Debus J. A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells. J. Mol. Biol. 2002; 318: 237-243
27. Pipkorn R, Waldeck W, Didinger B, Koch M, Mueller G, Wiessler M, and Braun K. Inverse-electron-demand Diels-Alder reaction as a highly efficient chemoselective ligation procedure: Synthesis and function of a BioShuttle for temozolomide transport into prostate cancer cells. J. Pept. Sci. 2009; 15: 235-241
28. Ehemann V, Sykora J, Vera-Delgado J, Lange A, and Otto HF. Flow cytometric detection of spontaneous apoptosis in human breast cancer using the TUNEL-technique. Cancer Lett. 2003; 194: 125-131
29. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P, and Breuhahn K. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 2007 Sep;46(3):759-68
30. Tschaharganeh D, Ehemann V, Nussbaum T, Schirmacher P, and Breuhahn K. Non-specific Effects of siRNAs on Tumor Cells with Implications on Therapeutic Applicability Using RNA Interference. Pathol. Oncol. Res. 2007; 13: 84-90
31. Stathopoulos GP, Koutantos J, Vaslamatzis MM, Athanasiadis A, Papadopoulos G, Labrodimou G, Stathopoulos J, and Rigatos S. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: A phase II study. Oncol. Rep. 2009; 22: 345-348
32. Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagoz S, Rosenberg E, Hadley WK, and Nikaido H. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 1995; 39: 2620-2624
33. Newton RU, Taaffe DR, Spry N, Gardiner RA, Levin G, Wall B, Joseph D, Chambers SK, and Galvao DA. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC. Cancer 2009; 9: 210
34. Evan GI and Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348
35. Krammer PH, Behrmann I, Daniel P, Dhein J, and Debatin KM. Regulation of apoptosis in the immune system. Curr. Opin. Immunol. 1994; 6: 279-289
36. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374
37. Jurgensmeier JM and Bauer G. Interference of bcl-2 with intercellular control of carcinogenesis. Int. J. Cancer 1997; 71: 698-704
38. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17: 3225-3236
39. Li Y and Cozzi PJ. Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev. 2009 [Epub ahead of print]
40. Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, and Takei Y. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int. J. Cancer 2009;125(12):2978-90
41. Cherry J, Karschner V, Jones H, and Pekala PH. HuR, an RNA-binding protein, involved in the control of cellular differentiation. In Vivo 2006; 20: 17-23
42. Zhang T, Kruys V, Huez G, and Gueydan C. AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors. Biochem. Soc. Trans. 2002; 30: 952-958
43. Niesporek S, Kristiansen G, Thoma A, Weichert W, Noske A, Buckendahl AC, Jung K, Stephan C, Dietel M, and Denkert C. Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int. J. Oncol. 2008; 32: 341-347
44. Meisner NC, Hackermuller J, Uhl V, Aszodi A, Jaritz M, and Auer M. mRNA openers and closers: modulating AU-rich element-controlled mRNA stability by a molecular switch in mRNA secondary structure. Chembiochem. 2004; 5: 1432-1447
45. Lammers T, Subr V, Peschke P, Kuhnlein R, Hennink WE, Ulbrich K, Kiessling F, Heilmann M, Debus J, Huber PE, and Storm G. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br. J. Cancer 2008; 99: 900-910
46. Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, and Storm G. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 2009; 30: 3466-3475
47. Braun K, Wiessler M, Ehemann V, Pipkorn R, Spring H, Debus J, Didinger B, Koch M, Muller G, and Waldeck W. Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry. Drug Design. Development and Therapy 2008; 2: 289-301
48. Waldeck W, Wiessler M, Ehemann V, Pipkorn R, Spring H, Debus J, Didinger B, Mueller G, Langowski J, and Braun K. TMZ-BioShuttle - a reformulated temozolomide. Int. J. Med. Sci. 2008; 5: 273-284
49. Powell SN and Bindra RS. Targeting the DNA damage response for cancer therapy. DNA Repair (Amst) 2009; 8: 1153-1165
50. Shimada M and Nakanishi M. DNA damage checkpoints and cancer. J. Mol. Histol. 2006; 37: 253-260
51. Damia G and Broggini M. Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell Cycle 2004; 3: 46-50
52. Fournier C and Taucher-Scholz G. Radiation induced cell cycle arrest: an overview of specific effects following high-LET exposure. Radiother. Oncol. 73 Suppl 2004; 2: S119-S122
53. Pawlik TM and Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004; 59: 928-942
54. Trog D, Moenkemann H, Breipohl W, Schueller H, Schild H, and Golubnitschaja O. Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions. Amino. Acids 2007; 32: 373-379
55. Lukusa T and Fryns JP. Human chromosome fragility. Biochim. Biophys. Acta 2008;1779:3-16
56. Lieberthal W, Koh JS, and Levine JS. Necrosis and apoptosis in acute renal failure. Semin. Nephrol. 1998; 18: 505-518
57. Tisdale MJ, Antitumor imidazotetrazines - XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem. Pharmacol. 1987; 36: 457-462
58. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, and Jenkins RB. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl. Cancer Inst. 1999; 91: 1574-1580
59. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, and Linehan WM. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 1995; 55: 2959-2962
60. DePinho RA, Schreiber-Agus N, and Alt FW. myc family oncogenes in the development of normal and neoplastic cells. Adv. Cancer Res. 1991; 57: 1-46
61. Jenkins RB, Qian J, Lieber MM, and Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 1997; 57: 524-531
62. van Heerden WF, Dreyer L, Swart TJ, van Heerden MB, and Boy SC. The suitability of paraffin-embedded material to predict metastatic potential of oral squamous cell carcinoma. Anticancer Res. 2002; 22: 4147-4150